What actually manages PCOS, according to the international guideline

There is no cure for polycystic ovary syndrome, but there is a clear, evidence-graded playbook for managing its main effects, and it is less exotic than the supplement market implies. The 2023 International Evidence-based Guideline — the most comprehensive assessment of the condition, developed across 39 organisations covering 71 countries — puts healthy lifestyle first for all women with PCOS, letrozole first when the goal is pregnancy, and the combined pill first for irregular cycles and excess hair [s1]. It also does something most guidelines avoid: it rates much of its own supporting evidence as low to moderate quality [s1].

PCOS is common — it affects an estimated 10-13% of reproductive-aged women, and up to 70% of those affected are undiagnosed — and it is the most common cause of anovulation [s2]. That scale is part of why the gap between what is marketed and what is supported matters.

Lifestyle first, for everyone

The guideline's foundational recommendation is that lifestyle measures — healthy eating, physical activity and behavioural strategies — "should be recommended for all women with PCOS, for improving metabolic health including central adiposity and lipid profile" [s1]. This is framed as a baseline for the whole condition, not a weight-loss instruction, and the guideline explicitly pairs it with awareness of weight stigma [s1].

That emphasis reflects the guideline's broader repositioning of PCOS as a metabolic and psychological condition as much as a reproductive one, with strengthened recognition of cardiovascular risk factors, sleep apnoea and a "very high prevalence of psychological features" [s1].

For fertility: letrozole, not what many expect

When the goal is pregnancy in women who are not ovulating, the guideline is unambiguous: "Letrozole should be the first-line pharmacological treatment for ovulation induction in infertile anovulatory women with PCOS, with no other infertility factors," a recommendation it grades at its highest evidence level [s1]. It notes that letrozole, metformin and clomiphene are all used off-label for this purpose in many countries [s1].

This is a case where the evidence has moved ahead of habit: letrozole, a drug originally developed for breast cancer, outperformed the older clomiphene for this use, and the guideline reflects that — part of its stated aim to emphasise "cheaper and safer fertility management" [s1].

For cycles and excess hair: the combined pill

For managing irregular periods and the hirsutism and acne driven by excess androgens, the guideline supports the combined oral contraceptive pill, including in adolescents at risk of or diagnosed with PCOS [s1]. Metformin is positioned as an option that targets metabolic features and can be combined with other therapies [s1].

For higher weight specifically, the guideline says anti-obesity medications — it names liraglutide and semaglutide among GLP-1 receptor agonists, and orlistat — "could be considered, in addition to active lifestyle intervention," as in the general population [s1]. That is a measured endorsement, not a headline cure.

The supplement question: inositol

Inositol, heavily marketed for PCOS, gets a deliberately modest placement. The guideline states that inositol "could be considered in women with PCOS based on individual preferences and values, noting limited harm" and potential metabolic improvement [s1]. That is the language of a weak, optional recommendation resting on limited evidence — a long way from the confident claims made in its marketing [s1].

The honest caveat the guideline makes about itself

The most useful thing about this guideline may be its candour on evidence quality. It rests on roughly 6,000 pages of technical evidence review and issues 254 recommendations and practice points, yet it repeatedly notes that the underlying evidence "remains generally low to moderate quality" and calls for "significantly greater research" into a common but neglected condition [s1]. Diagnosis is still frequently delayed, and it added anti-Müllerian hormone blood testing as an alternative to ultrasound for diagnosis in adults [s1].

For a reader, the practical shape is this: the interventions with the strongest backing are unglamorous and widely available — lifestyle support, letrozole for fertility, the pill for cycles and androgen symptoms — while the treatments that dominate online discussion, from inositol to the newer weight drugs, sit in the "could be considered" tier where the evidence is thinner [s1]. None of it is a cure, because none exists yet [s2].

This article is informational and is not medical advice. PCOS management should be individualised with a clinician, who can weigh symptoms, goals and health history.

Sources

• Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — Journal of Clinical Endocrinology & Metabolism / Human Reproduction, 2023-08-15
• Polycystic ovary syndrome (fact sheet) — World Health Organization, 2026-01-22